Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Optimer Pharmaceuticals (UNKNOWN:UNKNOWN) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Optimer and see what CAPS investors are saying about the stock right now.

Optimer facts

Headquarters (founded)

San Diego, Calif. (1998)

Market Cap

$599.0 million

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$101.5 million

Management

Chairman/CEO Henry McKinnell
CFO Stephen Webster

Return on Equity (average, past 3 years)

(47.3%)

Cash/Debt

$124.0 million / $0

Competitors

Bayer
Pfizer
Sanofi

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 27% of the 149 members who have rated Optimer believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star zzlangerhans, succinctly summed up the bear case for our community:

Optimer stock is weathering yet another quarter of disappointing Dificid revenues by floating the old "strategic alternatives " flag. Sometimes the sale happens, more often than not it doesn't. I remember that tactic didn't work out very well for [Savient Pharmaceuticals]. Dificid has been a confusing underperformer, given that clostridium difficile infection continues to be a crisis in the US health care system and the available therapeutics are clearly insufficient. Perhaps a larger pharma feels like they have the skills to make Dificid more profitable, but I suspect antibiotics are a relatively low priority for most of those companies. Even if a buyout does occur, I think it will take long enough that most of the short-term momo traders will get bored and exit.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.